Report Library
All ReportsDatamonitor Healthcare I&I Disease Analysis: Rheumatoid Arthritis (RA)
October 21, 2024
The rheumatoid arthritis market is set to experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance of biosimilars compared to other regions. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars, encouraging uptake.
As multibillion-dollar products, Humira and Enbrel represent the best-selling brands in the market, but since Humira's 2023 patent expiry in the US, 10 adalimumab biosimilars with discounts ranging from 5% to 85% have slowly begun to chip away at the originator brand's stronghold. However, etanercept biosimilars remain held in patent litigation, potentially giving branded Enbrel until 2029 before it could face the same fate as Humira.
Indications Covered: | Rheumatoid Arthritis (RA) |